The molecular regulation of Janus kinase (JAK) activation

Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation

(2014) Camilla Pilati et al.   CANCER CELL

Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis

(2014) Xingming Zhang et al.   CLINICAL RHEUMATOLOGY

Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia

(2014) J. Grisouard et al.   HAEMATOLOGICA

Structural basis of recognition of interferon-α receptor by tyrosine kinase 2

(2014) Heidi J A Wallweber et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition

(2014) P. J. Lupardus et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor

(2014) A. J. Brooks et al.   SCIENCE

Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem Cells

(2014) Hajime Akada et al.   STEM CELLS

Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance

(2014) Raimund M. Vielnascher et al.   TRANSGENIC RESEARCH

SUMOylation is a regulator of the translocation of Jak2 between nucleus and cytosol

(2013) Magdalena Sedek et al.   BIOCHEMICAL JOURNAL

Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses

(2013) Leila N. Varghese et al.   BIOCHEMICAL JOURNAL

A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties

(2013) James M. Murphy et al.   BIOCHEMICAL JOURNAL

The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism

(2013) James M. Murphy et al.   IMMUNITY

Structure-guided studies of the SHP-1/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition

(2013) Nilda L. Alicea-Velázquez et al.   JOURNAL OF STRUCTURAL BIOLOGY

On the Regulation and Activation of JAK2: A Novel Hypothetical Model

(2013) Tai-Sung Lee   MOLECULAR CANCER RESEARCH

Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases

(2013) Angela V Toms et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition

(2013) Nadia J Kershaw et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans

(2013) Sung O. Park et al.   PLoS One

Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling

(2013) I. Louria-Hayon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia

(2012) M. Porcu et al.   BLOOD

Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project

(2012) M. L. Loh et al.   BLOOD

The biology and mechanism of action of suppressor of cytokine signaling 3

(2012) Jeffrey J. Babon et al.   GROWTH FACTORS

Genotype-Phenotype Interactions in the Myeloproliferative Neoplasms

(2012) Anna L. Godfrey et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Suppression of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition and the Basis of Its Specificity

(2012) Jeffrey J. Babon et al.   IMMUNITY

A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome

(2012) Sara S. Kilic et al.   JOURNAL OF PEDIATRICS

Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

(2012) Priya Koppikar et al.   NATURE

Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F

(2012) Rajintha M Bandaranayake et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations

(2011) F. Passamonti et al.   BLOOD

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group

(2011) J. Zhang et al.   BLOOD

PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia

(2011) M. Kleppe et al.   BLOOD

JAKs go nuclear: Emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth

(2011) Fouad A. Zouein et al.   GROWTH FACTORS

The role of the N-terminal domain in dimerization and nucleocytoplasmic shuttling of latent STAT3

(2011) M. Vogt et al.   JOURNAL OF CELL SCIENCE

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling

(2011) Daniela Ungureanu et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Structural Snapshots of Full-Length Jak1, a Transmembrane gp130/IL-6/IL-6Rα Cytokine Receptor Complex, and the Receptor-Jak1 Holocomplex

(2011) Patrick J. Lupardus et al.   STRUCTURE

PTP1B Suppresses Prolactin Activation of Stat5 in Breast Cancer Cells

(2010) Kevin J. Johnson et al.   AMERICAN JOURNAL OF PATHOLOGY

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms

(2010) S. T. Oh et al.   BLOOD

Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice

(2010) S. P. Gorantla et al.   BLOOD

Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms

(2010) F. Baran-Marszak et al.   BLOOD

Tyrosines 868, 966, and 972 in the Kinase Domain of JAK2 Are Autophosphorylated and Required for Maximal JAK2 Kinase Activity

(2010) Lawrence S. Argetsinger et al.   MOLECULAR ENDOCRINOLOGY

Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia

(2010) Maria Kleppe et al.   NATURE GENETICS

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors

(2010) Alexandra Dusa et al.   PLoS One

A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation

(2009) Lequn Zhao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulation of Jak2 Function by Phosphorylation of Tyr317 and Tyr637 during Cytokine Signaling

(2009) S. A. Robertson et al.   MOLECULAR AND CELLULAR BIOLOGY

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

JAK mutations in high-risk childhood acute lymphoblastic leukemia

(2009) C. G. Mullighan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes

(2008) G. Wernig et al.   BLOOD

Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway

(2008) Megumi Funakoshi-Tago et al.   CELLULAR SIGNALLING

Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers

(2008) E. G. Jeong et al.   CLINICAL CANCER RESEARCH

Somatically acquiredJAK1mutations in adult acute lymphoblastic leukemia

(2008) Elisabetta Flex et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias

(2008) Wanlong Ma et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

(2008) Dani Bercovich et al.   LANCET